Latest Us Market News

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Ionic Rare Earths (ASX: IXR) has secured a £12 million UK government grant offer for its Belfast rare earth magnet recycling facility and is progressing its Brazilian JV and Ugandan heavy rare earths project, reinforcing its role in ex-China supply chains.

Brazilian Critical Minerals (ASX: BCM) has reinforced the scale and quality of its Ema rare earth project with strong drilling results and steady progress on permitting and feasibility studies, positioning it well amid tightening global supply.

Resolution Minerals has raised A$20 million in a strongly supported institutional placement to accelerate exploration and development at its US Horse Heaven Project, while preparing for a NASDAQ listing to boost its US market presence.

Pureprofile delivered a robust Q3 FY26 with 17% revenue growth and a 67% spike in EBITDA, driven by strong international demand and a doubling of platform revenue. The company reaffirmed its FY26 guidance amid ongoing macroeconomic caution.

Airtasker Limited posted robust 3Q26 results highlighted by strong Australian marketplace momentum and explosive growth in the UK and US. The company reaffirmed its FY26 guidance, underpinned by strategic media partnerships and a solid cash position.

Nova Minerals has secured ASIC registration of its Scheme Booklet for re-domiciling to the US, alongside amendments to warrant terms that triple warrant exchange ratios ahead of the move.

Treasury Wine Estates is reshaping its global operations into four regional divisions to sharpen market execution and efficiency. The company reports improved third-quarter sales in China and the US, bolstered by luxury brand Penfolds, while securing $300 million in new debt to strengthen liquidity beyond $1 billion by fiscal 2026 end.

Firebrick Pharma secured regulatory approval for Nasodine Nasal Spray in Indonesia and launched Nasodine Throat Spray in Singapore and Fiji, while raising $1.5 million to fuel growth. The company aims to quadruple its product and market footprint within three years.

Starpharma has secured FDA alignment on the clinical development plan for its DEP® HER2 radiotherapy candidate, paving the way for a first-in-human phase 1 study in advanced HER2-positive cancers scheduled for H2 2026.

Compumedics maintains robust sales momentum but faces FY26 revenue timing challenges due to MEG installation delays and a cautious Somfit D rollout. The company expects solid year-on-year growth and positions for improved execution in FY27.

QuickFee reported a 9% normalised revenue decline in Q3 FY26, driven by US finance weakness post-US Pay Now sale, while Australian legal disbursement funding surged, underpinning confidence in FY26 earnings guidance.